This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated Sep 2026 quarter revenue up 79.7%, profit after tax up 1,259% versus Sep 2025
BODALCHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.7 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the consolidated quarter ended 30 September 2026, revenue from operations rose 79.7% to Rs 8,633.74 million from Rs 4,804.52 million a year earlier; profit after tax rose 1,259.0% to Rs 814.44 million from Rs 59.93 million. EBITDA margin widened 7.6 percentage points to 12.4% from 4.8%. A Rs 12.72 million Turkish hyperinflation restatement charge reduced pre-tax profit; the limited review was unmodified.
Strong revenue, profit and margin gains should support investor sentiment, though results are unaudited and the Turkish restatement adds uncertainty.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹863.4 Cr | ₹480.5 Cr | +79.7% |
| Operating profit | ₹69.41 Cr | −₹14.34 Cr | turned positive |
| Profit after tax | ₹81.44 Cr | ₹5.99 Cr | +1,259.0% |
| EBITDA margin | 12.4% | 4.8% | +7.6 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.